key: cord-0858474-i796b8bi
authors: Volpato, F.; Lima-Morales, D.; Wink, P. L.; Willig, J.; de-Paris, F.; Ashton-Prolla, P.; Barth, A. L.
title: Pooling of samples to optimize SARS-CoV-2 diagnosis by RT-qPCR: comparative analysis of two protocols.
date: 2020-08-26
journal: nan
DOI: 10.1101/2020.08.24.20181008
sha: 5d7a8803232d8536f820af83cefb51d7178bb002
doc_id: 858474
cord_uid: i796b8bi

RT-qPCR for SARS-CoV-2 is the main diagnostic test used to identify the novel coronavirus. Several countries have used large scale SARS-CoV-2 RT-qPCR testing as one of the important strategies for combating the pandemic. In order to process the massive needs for coronavirus testing, the usual throughput of routine clinical laboratories has reached and often surpassed its limits and new approaches to cope with this challenge must be developed. This study has aimed to evaluate the use pool of samples as a strategy to optimize the diagnostic of SARS-CoV-2 by RT-qPCR in a general population. A total of 220 naso/orofaryngeal swab samples were collected and tested using two different protocols of sample pooling. In the first protocol (Protocol A); 10 clinical samples were pooled before RNA extraction. The second protocol (Protocol B) consisted of pooling the already extracted RNAs from 10 individual samples. Results from Protocol A were identical (100% agreement) with the individual results. However, for results from Protocol B, reduced agreement (91%) was observed in relation to results obtained by individual testing. Inconsistencies observed were related to RT-qPCR results with higher Cycle Thresholds (Ct > 32.73). Furthermore, in pools containing more than one positive individual, the Ct of the pool was equivalent to the lowest Ct among the individual results. These results provide additional evidence in favor of the clinical use of pooled samples for SARS-CoV-2 diagnosis by RT-qPCR and suggest that pooling of samples before RNA extraction is preferrable in terms of diagnostic yield.

2 Abstract 27 RT-qPCR for SARS-CoV-2 is the main diagnostic test used to identify the novel 28 coronavirus. Several countries have used large scale SARS-CoV-2 RT-qPCR testing as 29 one of the important strategies for combating the pandemic. In order to process the 30 massive needs for coronavirus testing, the usual throughput of routine clinical laboratories 31 has reached and often surpassed its limits and new approaches to cope with this 32 challenge must be developed. This study has aimed to evaluate the use pool of samples 33 as a strategy to optimize the diagnostic of SARS-CoV-2 by RT-qPCR in a general 34 population. A total of 220 naso/orofaryngeal swab samples were collected and tested is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

Due to the exponential increase of respiratory syndromes by SARS-CoV-2, the 51 World Health Organization (WHO) declared COVID-19 a pandemic of worldwide 52

importance (1) . The rapid propagation of the virus significantly increases the demand on 53 the health care system. In response to the challenge of identifying and isolating infected 54 patients, in an attempt to minimize spread of the disease, two different types of tests have 55 been used: real time Reverse Transcriptase Polymerase Chain Reaction (RT-qPCR) for 56 SARS-CoV-2 diagnosis mainly in upper respiratory tract samples and serum IgM and/or 57 IgG antibody detection assays to detect past infection and possibly immunity to the 58

In order to avoid diagnostic cross-reactivity with other endemic coronaviruses, most 60 RT-qPCR assays include primers for at least two different molecular targets, such as 61 nucleocapsid proteins 1 (N1) and 2 (N2) (2). A major advantage of real time assays is that 62 amplification and analysis of the final product are performed simultaneously in a closed is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 26, 2020. . https://doi.org/10.1101/2020.08.24.20181008 doi: medRxiv preprint extreme scenario. In this brief report, we provide additional evidence in favor of SARS-75

CoV-2 RT-qPCR analysis with pooled samples using two different methodologies. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 26, 2020. . https://doi.org/10.1101/2020.08.24.20181008 doi: medRxiv preprint result was considered "negative" when neither N1 nor N2 targets amplified and "positive" 101 when both N1 and N2 targets amplified. RT-qPCR was considered "inconclusive" when is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 26, 2020. . https://doi.org/10.1101/2020.08.24.20181008 doi: medRxiv preprint in pools with more than one positive sample, Ct of the pool was similar to the lowest Ct 127 obtained in the individual analyses of the samples included in the pool (Table 1) and high specificity and has been regarded as the "gold standard" for the virus genome 134 detection (4). However, it is still a semi-automated strategy which includes several 135 sequential analytical steps and is associated with significant costs. Sample pooling is a 136 well known approach to optimize time and costs of massive screening strategies for 137 infectious diseases and has been reported as a reliable technique for Hepatitis B, Hepatitis 138

In this study, we demonstrate that RT-qPCR with primers for the nucleocapsid of is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 26, 2020. . https://doi.org/10.1101/2020.08.24.20181008 doi: medRxiv preprint performance whether the population in analysis is expected to present low incidence of the 152 COVID-19 such as people without symptoms, for example. 153

The best performance of Protocol A in relation to Protocol B in our study is probably 154 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 26, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 26, 2020. . https://doi.org/10.1101/2020.08.24.20181008 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 26, 2020. . https://doi.org/10.1101/2020.08.24.20181008 doi: medRxiv preprint 

COVID-19: Epidemiology, Evolution, and Cross-Disciplinary 186

COVID-19: Current Issues and Challenges

Transcription-PCR assay panel for Middle East Respiratory Syndrome Coronavirus

Recent 196 advances and perspectives of nucleic acid detection for coronavirus

Paving the road for rapid detection and Point-of-Care diagnostics

Pooling of 202 samples for testing for SARS-CoV-2 in asymptomatic people

Chapter 6: Nucleic Acid Amplification

Molecular Diagnostics: Fundamentals, Methods, and Clinical

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted August 26, 2020. . https://doi.org/10.1101/2020.08.24.20181008 doi: medRxiv preprint